General information
Immatics Biotechnologies GmbH
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Harpreet Singh, CEO
Company main phone: +49 (7071) 53970
Company main fax: +49 (7071) 5397900
Website: https://www.immatics.com
Year founded: | 2000
|
Source of foundation: | Spin-off from university |
Name of foundation source: | H.G. Rammensee's laboratory at the University of Tübingen, Germany |
No. of employees: |
Worldwide: 210 |
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company’s product candidates are adoptive cell therapies and bispecific TCR molecules.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2020
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Cell therapy
- Immunotherapy
|
Primary therapeutic areas: |
- Neoplasms / cancer / oncology
|
Business model: |
- In-licensing
- Out-licensing
- R&D
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Distribution: |
- Indirect (independent dealer)
|
Summary Products / Services / Technologies
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
Financing details
Market cap. / valuation: | USD 516.76M | |
Collaborations & Clients
Partnering strategy / collaborations:
Amgen
MDACC
MorphoSys
Roche
Genmab